Advertisement

Journal of Robotic Surgery

, Volume 13, Issue 3, pp 515–517 | Cite as

Robot-assisted abdominal wall excision of a PSMA-detected prostate cancer metastasis

  • D. MoranEmail author
  • T. Gross
  • D. Gavin
  • A. J. Costello
Case Report
  • 54 Downloads

Abstract

Recent advances in novel functional imaging techniques such as PSMA PET may now offer the ability to identify small volume metastases which may otherwise go undetected. The treatment of these lesions is controversial, particularly in the oligometastatic state. We report the case of an abdominal wall metastasis detected with PSMA imaging which we treated with surgical excision. This resulted in an undetectable PSA 6 weeks post excision.

Keywords

Prostate cancer metastasis Oligometastatic disease PSMA PET Robotic excision 

Notes

Compliance with ethical standards

Conflict of interest

Authors D. Moran, T. Gross, D. Gavin, A. J. Costello declare that they have no conflict of interest.

Informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. Written informed consent was obtained from the patient for publication of this Case. Report/any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

References

  1. 1.
    De Bruyne P, Schatteman P, De Naeyer G, Carpentier P, Mottrie A (2015) Port site metastasis in prostate cancer. Can Urol Assoc J. 9(5–6):E387CrossRefGoogle Scholar
  2. 2.
    McLoughlin LC Moran D, O’Rourke C, Manecksha RP, Lynch TH (2018) The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy. Ir J Med Sci 187(1):261–268CrossRefGoogle Scholar
  3. 3.
    Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH (2012) Atypical metastases from prostate cancer: 10-year experience at a single institution. Am J Roentgenol 199(2):367–372CrossRefGoogle Scholar
  4. 4.
    Nair R, Lamb BW, Geurts N, Alghazo O, Lawrentschuk N, Murphy DG (2017) The role of local therapy for oligometastatic prostate cancer: should we expect a cure? Urol Clin North Am 44(4):623–633CrossRefGoogle Scholar
  5. 5.
    Nguyen PL, Alibhai SM, Basaria S et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825–836CrossRefGoogle Scholar
  6. 6.
    Dundee P, Gross T, Moran D, Ryan A, Ballok Z, Peters J, Costello AJ (2018) Ga-labeled Prostate-Specific Membrane Antigen Ligand-Positron-Emission Tomography: Still Just the Tip of the Iceberg. Urology. https://doi.org/10.1016/j.urology.2018.06.029Google Scholar
  7. 7.
    Murphy DG, Kerger M, Crowe H, Peters JS, Costello AJ (2009) Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy. Eur Urol 55(6):1358–1366CrossRefGoogle Scholar
  8. 8.
    Ochoa C, Ramirez A, Varela R et al (2017) Metastasectomy of abdominal wall lesions due to prostate cancer detected through PET/CT gallium 68-PMSA: first case report. Urol Case Rep 12:42–44CrossRefGoogle Scholar
  9. 9.
    Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.The Royal Melbourne HospitalMelbourneAustralia
  2. 2.University of MelbourneVictoriaAustralia
  3. 3.Australian Prostate CentreMelbourneAustralia
  4. 4.Department of UrologyUniversity of BernBernSwitzerland

Personalised recommendations